9 Meters Biopharma
NMTR
NMTR was delisted on the 25th of July, 2023.
38 hedge funds and large institutions have $7.23M invested in 9 Meters Biopharma in 2019 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 10 increasing their positions, 10 reducing their positions, and 9 closing their positions.
8,900% more call options, than puts
Call options by funds: $90K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 10
2% less capital invested
Capital invested by funds: $7.38M → $7.23M (-$146K)
3% less funds holding
Funds holding: 39 → 38 (-1)
11% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
+$928K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$677K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$119K |
| 4 |
SG Americas Securities
New York
|
+$31.5K |
| 5 |
ARTA
A.R.T. Advisors
New York
|
+$30.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$330K |
| 2 |
MFG
Magnus Financial Group
New York
|
-$114K |
| 3 |
BlackRock
New York
|
-$109K |
| 4 |
Morgan Stanley
New York
|
-$63.8K |
| 5 |
FQ
First Quadrant
Glendale,
California
|
-$55K |
NMTR Hedge Fund Activity: Q1 2019 in Review
38 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in 9 Meters Biopharma (NMTR) for Q1 2019, worth a combined $7.23M — down 2% from $7.38M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of NMTR and 8 opened new positions — a net loss of 1 holder — while 10 trimmed existing stakes and 10 added.
The largest buyer was Granite Point Capital Management, opening a new position worth an estimated $928K. The largest seller was Oxford Asset Management, exiting entirely with an estimated $330K sold.
- 38 institutional investors held 9 Meters Biopharma (NMTR) as of Q1 2019, down from 39 in Q4 2018.
- Funds reported $7.23M of 9 Meters Biopharma stock for Q1 2019, down 2% quarter-over-quarter.
- 8 funds opened new 9 Meters Biopharma positions in Q1 2019 and 9 closed out, a net change of -1 holder.
- The largest 9 Meters Biopharma buyer in Q1 2019 was Granite Point Capital Management, an estimated $928K added.
- The largest 9 Meters Biopharma seller in Q1 2019 was Oxford Asset Management, an estimated $330K sold.
Based on aggregated 13F filings for Q1 2019.